登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
ClinicalTrials.gov 上登记的一项视神经脊髓炎谱系疾病开放试验。牵头方不是本站收录的医院;本站收录的 27 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 27
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心首都医科大学附属北京天坛医院Beijing Tiantan Hospital北京医院页面
- 研究中心首都医科大学附属北京同仁医院Beijing Tongren Hospital北京医院页面
- 研究中心中国人民解放军总医院Chinese PLA General Hospital北京医院页面
- 研究中心福建医科大学附属第一医院First Affiliated Hospital of Fujian Medical University福州医院页面
- 研究中心昆明医科大学第一附属医院First Affiliated Hospital of Kunming Medical University昆明医院页面
- 研究中心中山大学附属第一医院First Affiliated Hospital of Sun Yat-sen University广州医院页面
- 研究中心中国科学技术大学附属第一医院(安徽省立医院)First Affiliated Hospital of USTC合肥医院页面
- 研究中心温州医科大学附属第一医院First Affiliated Hospital of Wenzhou Medical University温州医院页面
- 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
- 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
- 研究中心中国医科大学附属第一医院First Hospital of China Medical University沈阳医院页面
- 研究中心山西医科大学第一医院First Hospital of Shanxi Medical University太原医院页面
- 研究中心河南省人民医院Henan Provincial People's Hospital郑州医院页面
- 研究中心北京大学第一医院Peking University First Hospital北京医院页面
- 研究中心山东大学齐鲁医院Qilu Hospital of Shandong University济南医院页面
- 研究中心安徽医科大学第二附属医院Second Affiliated Hospital of Anhui Medical University合肥医院页面
- 研究中心哈尔滨医科大学附属第二医院Second Affiliated Hospital of Harbin Medical University哈尔滨医院页面
- 研究中心浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面
- 研究中心河北医科大学第二医院Second Hospital of Hebei Medical University石家庄医院页面
- 研究中心中南大学湘雅二医院Second Xiangya Hospital长沙医院页面
- 研究中心四川省人民医院Sichuan Provincial People's Hospital成都医院页面
- 研究中心中山大学孙逸仙纪念医院Sun Yat-sen Memorial Hospital广州医院页面
- 研究中心中山大学附属第三医院Third Affiliated Hospital of Sun Yat-sen University广州医院页面
- 研究中心天津医科大学总医院Tianjin Medical University General Hospital天津医院页面
- 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面
- 研究中心中南大学湘雅医院Xiangya Hospital长沙医院页面
- 研究中心厦门大学附属中山医院Zhongshan Hospital, Xiamen University厦门医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06413654,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 3
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(3 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
The blood pregnancy tests were negative within 7 days before the first dose in fertile female subjects. The fertile subjects and the male subjects whose partner are fertile woman agree to use reliable contraception during the study period and within 6 months after the study drug discontinuation;
入选标准第 3 条
Received anti-CD20 or other cell depletion therapy within 6 months before first dose;
排除标准第 3 条
Subjects who had undergone major surgery within 2 months prior to screening or were scheduled to undergo major surgery during the trial;
排除标准第 8 条
Pregnant or lactating women; Subjects with birth plans during the trial;
排除标准第 7 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06413654,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Confirmed NMOSD patients; Experienced at least 1 recurrence of NMOSD within 1 year or at least 2 recurrence within 2 years prior to screening; The blood pregnancy tests were negative within 7 days before the first dose in fertile female subjects. The fertile subjects and the male subjects whose partner are fertile woman agree to use reliable contraception during the study period and within 6 months after the study drug discontinuation; Volunteer to participate in clinical research; Fully understand and know the study and sign the informed consent; Willing to follow and able to complete all test procedures.排除标准:Exclusion Criteria:
Subjects with severe NMOSD were judged by the researcher to be unfit to participate in this study; Subjects with chronic active immune system diseases undergoing systematic treatment; Received anti-CD20 or other cell depletion therapy within 6 months before first dose; Received the prescribed drug treatment at the prescribed time before first dose; Subjects who have participated in any drug clinical trials within 28 days prior to the first dose; Received hematopoietic stem cell transplantation、 lymphatic irradiation before first dose; Pregnant or lactating women; Subjects with birth plans during the trial; Subjects who had undergone major surgery within 2 months prior to screening or were scheduled to undergo major surgery during the trial; Subjects with severe, progressive, or uncontrolled disease who have been assessed by the investigator to be at increased risk of participating in the study; A history of gastrointestinal perforation and/or fistula within 6 months prior to screening; Subjects who received a live or attenuated vaccine within 4 weeks prior to initial administration, or who plan to receive vaccination during the study period; Subjects with severe or persistent infection currently or within the 1 months prior to screening; Subjects with positive gamma interferon release test; Subjects who currently have active hepatitis or have a history of severe liver disease; Uncontrolled systemic disease, or any other reason the investigator deems inappropriate for inclusion; Abnormal laboratory test results; Subjects with a history of alcohol or drug abuse in the 6 months prior to screeing, or who are abusing; Subjects with symptoms of severe mental illness who are clinically uncooperative; Subjects who were unable to undergo magnetic resonance imaging during the study and who had other conditions that the investigator considered inappropriate to enroll.
引自 ClinicalTrials.gov, NCT06413654, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06413654,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。